Evaluation of a portable hemoglobinometer (HemoCue) to control anemia in hepatitis C liver transplant recipients undergoing antiviral therapy

European Journal of Gastroenterology and Hepatology

Volumn 23, Issue 10, 2011, Pages 942-947

  Mariño, Zoe ^a   Carrión, Jose Antonio ^a   Bedini, Josep Lluis ^b   Crespo, Gonzalo ^a   Martínez, Stella Maris ^a   Sánchez Tapias, José Maria ^a   Forns, Xavier ^a   Navasa, Miquel Angel ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

anemia; antiviral treatment; hepatitis C recurrence; liver transplantation; portable hemoglobinometer

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CAPILLARY BLOOD; CLINICAL ARTICLE; CORRELATION COEFFICIENT; COST CONTROL; CREATININE CLEARANCE; DIAGNOSTIC ACCURACY; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; HEMOGLOBIN DETERMINATION; HEMOGLOBINOMETER; HEPATITIS C; HUMAN; LIVER TRANSPLANTATION; MALE; PORTABLE EQUIPMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RECURRENT DISEASE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; VENOUS BLOOD;

ADULT; AGED; ANEMIA; ANTIVIRAL AGENTS; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HEMATOLOGIC TESTS; HEMOGLOBINOMETRY; HEMOGLOBINS; HEPATITIS C, CHRONIC; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POINT-OF-CARE SYSTEMS; POSTOPERATIVE CARE; RECURRENCE; REPRODUCIBILITY OF RESULTS;

EID: 80052682414     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328348f9c2     Document Type: Article

References (36)

1. Wright TL, Donegan E, Hsu HH, Ferrell L, Lake JR, Kim M, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992; 103:317-322.
2. Gane EJ, Naoumov NV, Qian KP, Mondelli MU, Maertens G, Portmann BC, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110:167-177. (Pubitemid 26021616)
3. Berenguer M, Wright TL. Hepatitis C and liver transplantation. Gut 1999; 45:159-163. (Pubitemid 29333757)
4. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32:673-684. (Pubitemid 30180389)
5. Garćia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35:680-687. (Pubitemid 34183974)
6. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334:815-820. (Pubitemid 26099603)
7. Prieto M, Berenguer M, Rayon JM, Cordoba J, Arguello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999; 29:250-256. (Pubitemid 29024010)
8. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayón M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32:673-684. (Pubitemid 30180389)
9. Garcia-Retortillo M, Forns X, Llovet JM, Navasa M, Feliu A, Masaguer A, et al. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004; 40:699-707. (Pubitemid 39265593)
10. Prieto M, Berenguer M, Rayon JM, Cordoba J, Arguello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999; 29:250-256. (Pubitemid 29024010)
11. Sanchez-Fueyo A, Restrepo JC, Quinto L, Bruguera M, Grande L, Sanchez-Tapias JM, et al. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation 2002; 73:56-63. (Pubitemid 34094685)
12. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122:889-896. (Pubitemid 34267271)
13. Blasco A, Forns X, Carrion JA, Garcia-Pagan JC, Gilabert R, Rimola A, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 2006; 43:492-499.
14. Carrion JA, Navasa M, Bosch J, Bruguera M, Gilabert R, Forns X. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl 2006; 12:1791-1798. (Pubitemid 44911805)
15. Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003; 124:642-650. (Pubitemid 36268483)
16. Berenguer M, Palau A, Fernández A, Benlloch S, Aguilera V, Prieto M, et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006; 12:1067-1076. (Pubitemid 44063780)
17. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061-1069.
18. WHO. Nutritional anaemias: report of a WHO scientific group. 1968 Geneva: World Health Organization (WHO Technical Report Series, No. 405).
19. Nicholas RM, Norris S. Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV-the role of epoetin, G-CSF and novel agents. Aliment Pharmacol Ther 2010; 31:929-937.
20. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49:274-287.
21. Carrión JA, Navasa M, Garćia-Retortillo M, García-Pagan JC, Crespo G, Bruguera M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterol 2007; 132:1746-1756. (Pubitemid 46695723)
22. Afdhal N, Dieterich DT, Pockros PJ, Schiff E, Shiffman ML, Sulkowski MS, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterol 2004; 126:1302-1311. (Pubitemid 38552795)
23. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, Reed A, Hemming A, Howard R, et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002; 8:1000-1006. (Pubitemid 35363625)
24. Vanzetti G. An azide-methemoglobin method for hemoglobin determination in blood. J Lab Clin Med 1966; 67:116-126.
25. Bäch SE, Magnusson CGM, Norlund LK, von Schenck HH, Menschik ME, Lindberg PES. Multiple-site analytic evaluation of a new portable analyzer, HemoCue Hb201 +, for point-of-care testing. Point of Care 2004; 3:60-65.
26. Lardi AM, Hirst C, Mortimer AJ, McCollum CN. Evaluation of the HemoCue for measuring intra-operative haemoglobin concentrations: a comparison with the Coulter Max-M. Anaesthesia 1998; 53:349-352. (Pubitemid 28162045)
27. Teli M, Ng Y, Ingram R. Evaluation of the HemoCue portable hemoglobinometer after major joint arthroplasty. J Arthroplasty 2002; 17:224-226. (Pubitemid 34160577)
28. Gehring H, Hornberger C, Dibbelt L, Roth-Isigkeit A, Gerlach K, Schumacher J, et al. Accuracy of point-of-care-testing (POCT) for determining hemoglobin concentrations. Acta Anaesthesiol Scand 2002; 46:980-986. (Pubitemid 34953683)
29. Muñoz M, Romero A, Gómez JF, Mantecas A, Naveira E, Ramírez R. Utility of point-of-care haemoglobin measurement in the HemoCue-B haemoglobin for the initial diagnosis of anaemia. Clin Lab Haem 2005; 27:99-104.
30. Muñoz M, Naveira E, Romero A, Cordero J, Gonzalez M, Raḿirez R. HemocueB Hemoglobin accuracy and reliability in inmediate determination of hemoglobin levels in patients on hemodialysis. Nefrologia 2004; XXIV:579-582. Article in Spanish. (Pubitemid 40247487)
31. Muñoz M, Naveira E, Romero A, Raḿirez R. Precision and accuracy of the inmediate determination of hemoglobin using HemoCueB hemoglobin in urgent, surgical, and critical patients. Rev Esp Anestesiol Reanim 2003; 50:332-339.
32. WHO/UNICEF/UNU. Iron deficiency anaemia: assessment, prevention and control, a guide for programme managers. 2001 Geneva: World Health Organization.
33. Hèzode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir and peginterferon with or without ribavirine for chronic HCV infection. N Engl J Med 2009; 360:1839-1850.
34. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362:1292-1303.
35. Kwo PY, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa 2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376:705-716.
36. Guillouche P, Feray C. Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation. Aliment Pharmacol Ther 2011; 33:163-174.